Medical and tech industry publications interview
Exec V.P. of U.S. Operations, Todd Durniak
CAESAREA, Israel, September 17, 2015 /PRNewswire/ — LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced the Dario has recently been featured in numerous U.S.-based media outlets including eHealth Radio, Mass Device, Personal Tech MD, and Boston Magazine.
Executive Vice President of U.S. Operations, Todd Durniak was recently interviewed on eHealth Radio, which produces health information, news, and advice featuring some of the leading innovators in healthcare and wellness. In the interview titled, “Managing Diabetes in the Digital World – Introducing the DARIO,” Durniak and host Eric Michaels discuss how the Dario uniquely improves the experience of glucose monitoring and disease management for those living with diabetes and their caregivers. Durniak mentions Labstyle’s Facebook community called the DARIO Lounge has helped Dario users around the world to connect and share their experience. To hear the interview in full please visit: http://ehealthradio.podbean.com/e/managing-diabetes-in-the-digital-world-%E2%80%93-introducing-the-dario
MassDevice.com, covering the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry, recently published an article titled, “Diabetes: LabStyle Innovations raises $2.3m for Dario device.” Describing the smartphone based all-in-one Dario, in the article, Durniak states, “I think with the advent of smartphone penetration into the market place, where 74% of Americans with cell phones have a smart phone, it allows us to do things with self-monitoring of health that we were never able to do before.” To read the article in full please visit: http://www.massdevice.com/diabetes-labstyle-innovations-raises-2-3m-for-dario-device/
Personal Tech MD
Personal Tech MD, a publication that focuses on patient-operated technology for medical use, published a case study on the Dario and how it changed the lives of two people living with type-1 diabetes. One of the case study subjects, a man living in England who has been using the Dario for the past year, stated the smartphone based glucose meter gives him a visual incentive to eat right and get exercise. He further stated that since using the Dario, he has had fewer hypoglycemic episodes and the ones he does have are less severe. To read the case study in full, please visit:
In an article titled, “New Technology Turns Smartphones Into Diabetes Testing Devices,” the Dario was featured in Boston Magazine, serving a half million monthly readers. The magazine interviewed Durniak, who pointed out the Dario can provide information that could lead to better diabetes treatments. Durniak was quoted as saying, “It allows you to really have a high-resolution view of how that person is living their day with diabetes. Then you can also amplify that across people very easily if they’re all using the device. That kind of data and power and resolution can lead to insight, and that’s what we hope this helps accomplish.” To read the article please visit:
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle’s flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “potential,” “seek,” “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate” or “continue” are intended to identify forward-looking statements. For example, we are using forward looking statements when we discuss that Dario uniquely improves the experience of glucose monitoring and disease management, or that Dario allows us to do things with self-monitoring of health that we were never able to do before, or that Dario can provide information that could lead to better diabetes treatments Readers are cautioned that certain important factors may affect the Company’s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company’s actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company’s filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company’s commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Press Investor Relations
1 800 896 9062